Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | TACR2 | P21452 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11421607 | 1.00 | ACHE (0.36) | ACHELIPGBACE1PTGS2ESR1 | |
| SCHEMBL8168465 | 0.98 | PTGS2 (0.33) | ACHELIPGBACE1PTGS2ESR1 | |
| Iodide SCHEMBL28429674 | 0.89 | NPC1 (0.32) | CHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL526149 | 0.82 | — | — | |
| SCHEMBL23920955 | 0.82 | ACHE (0.35) | ACHELIPGBACE1PTGS2ESR1 | |
| SCHEMBL22268975 | 0.82 | ACHE (0.35) | ACHELIPGBACE1PTGS2ESR1 | |
| SCHEMBL9574439 | 0.80 | PTGS2 (0.37) | ACHELIPGBACE1PTGS2ESR1 | |
| SCHEMBL10589751 | 0.80 | PTGS2 (0.37) | ACHELIPGBACE1PTGS2ESR1 | |
| SCHEMBL30727634 | 0.79 | CYP19A1 (0.36) | ACHELIPGBACE1PTGS2ESR1 | |
| SCHEMBL7719791 | 0.78 | PTGS2 (0.35) | ACHELIPGBACE1PTGS2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292421-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST | MITSUI CHEMICALS, INC. | 2010-11-18 | — | — | US | disclosed |
| EP-2218725-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST USING THE COMPOUND AND ETHYLENE POLYMER OBTAINED BY USING THE CATALYST | Mitsui Chemicals, Inc. (JP) | 2010-08-18 | — | — | EP | disclosed |
| EP-0963382-B2 | POLYMERIZATION CATALYST SYSTEMS COMPRISING HETEROCYCLIC FUSED CYCLOPENTADIENIDE LIGANDS | EXXONMOBIL CHEM PATENTS INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-6451938-B1 | CATALYTIC COMPLEX FORMED BY ACTIVATING TRANSITION METAL COMPOUNDS COMPRISING CYCLOPENTADIENIDE ANIONS WHICH BEAR FUSED HETEROCYCLIC RINGS | EXXON MOBIL CHEMICAL PATENTS INC. | 2002-09-17 | — | — | US | disclosed |
| EP-0963382-B1 | POLYMERIZATION CATALYST SYSTEMS COMPRISING HETEROCYCLIC FUSED CYCLOPENTADIENIDE LIGANDS | EXXONMOBIL CHEM PATENTS INC (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-0963382-A1 | POLYMERIZATION CATALYST SYSTEMS COMPRISING HETEROCYCLIC FUSED CYCLOPENTADIENIDE LIGANDS | EXXON CHEMICAL PATENTS INC. (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1998037106-A1 | POLYMERIZATION CATALYST SYSTEMS COMPRISING HETEROCYCLIC FUSED CYCLOPENTADIENIDE LIGANDS | EXXON CHEMICAL PATENTS INC. (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292421-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST | CAD, ENDOD1, CCT7 | ACHE 2662/4885LIPG 3339/4885BACE1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.